Bookmark

Add to MyYahoo RSS

MannKind News

News on MannKind (Ticker: MNKD) continually updated from thousands of sources around the net.

Friday Apr 11 | Seeking Alpha

The Stalled State Of MannKind

MannKind stock peaked in the wee hours of pre-market trading the day following a near unanimous adcom victory, but might not equal that fondly remembered price for years to come.

Comment?

Related Topix: Biotech

Friday Apr 11 | Sys-Con Media

FDA Recommendations, Study Publications, Recognitions, Agreements,...

Today, Analysts Review released its analysts' notes regarding MannKind Corp. , Acceleron Pharma, Inc. , Steris Corp. , Retrophin, Inc. , and NxStage Medical, Inc. .

Comment?

Related Topix: Food and Drug Administration, Medicine, Steris Corporation, Medical Equipment, Healthcare Industry, Biotech, NxStage Medical

Tue Apr 08, 2014

AmericanBankingNews.com

MannKind Receives New Coverage from Analysts at Brinson Patrick

Shares of MannKind opened at 6.32 on Tuesday. MannKind has a 52 week low of $3.72 and a 52 week high of $8.70.

Comment?

Related Topix: Biotech

Mon Apr 07, 2014

BioSpace

MannKind Corporation Drops As The FDA Delays Decision On Inhaled Insulin Treatment

MannKind Updates Status of New Drug Application for AFREZZA VALENCIA, Calif., Apr 07, 2014 -- MannKind Corporation MNKD -12.25% today announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for AFREZZAA by three months to July 15, 2014 in order to provide time for a full review of information ... (more)

Comment?

Related Topix: Biotech, Food and Drug Administration, Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health

Thu Apr 03, 2014

Sys-Con Media

The Zacks Analyst Blog Highlights: Gilead, MannKind, Cubist, Regeneron and Medicines Co

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

Comment?

Related Topix: Biotech, Medicines Company The, Medicine, Healthcare Industry, Financial Markets, Cubist Pharmaceuticals, Gilead Sciences, Regeneron Pharmaceuticals

Seeking Alpha

How MannKind Shows Depth Of The Diabetes Market

MannKind's surprise recommendation of approval for its diabetic inhaler by a Food and Drug Administration panel this week provides another platform to discuss this multibillion area of pharmaceuticals.

Comment?

Related Topix: Medicine, Diabetes, Health, Biotech, Food and Drug Administration, GlaxoSmithKline, Healthcare Industry, Bristol Myers Squibb

Minyanville

Pre-Market: US Economy Adds 191,000 Private Sector Jobs; Shares of...

Before the opening bell, Dow Jones futures rose 0.11% to 16,467. Futures on the S&P 500 were up 0.06% to 1,879.00.

Comment?

Related Topix: Biotech, Financial Markets, Monsanto, Chemicals

Wed Apr 02, 2014

Forbes.com

Shares Of MannKind, Intuitive Surgical Soar On FDA OKs

The Food and Drug Administration controls the food on your plate and the medication used to treat your ailments.

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Diabetes, Health, Financial Markets

Connecticut Post

Mannkind's inhaled insulin clears big

Danbury-based MannKind's hopes for Afrezza, an inhaled diabetes drug, took a major step forward this week when an advisory panel recommended the Food and Drug Administration approve the treatment.

Comment?

Related Topix: Biotech, Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health, Food and Drug Administration, Sales

Benzinga

Mid-Afternoon Market Update: MannKind Hangs Onto its Gains as Yelp Shares Drop

Toward the end of trading Wednesday, the Dow traded up 0.18 percent to 16,562.46 while the NASDAQ surged 0.05 percent to 4,270.78.

Comment?

Related Topix: Biotech, Media, Computers, Autobytel, VisionChina Media, US Energy, Energy, Oil & Gas, Liquidity Services, Financial Markets

Benzinga

Mid-Day Market Update: Apollo Drops After Q2 Results; MannKind Shares Spike Higher

Midway through trading Wednesday, the Dow traded up 0.11 percent to 16,551.46 while the NASDAQ surged 0.09 percent to 4,271.78.

Comment?

Related Topix: Apollo Group, Biotech, Media, Computers, Autobytel, VisionChina Media, US Energy, Energy, Oil & Gas, Liquidity Services

AmericanBankingNews.com

MannKind PT Lowered to $5.00

Cowen and Company's price objective would suggest a potential upside of 24.38% from the company's current price.

Comment?

Related Topix: Biotech

Minyanville

MannKind Doubles on FDA News, Could Drive Short Covering in Biotech Sector

You will receive a download link right in your email inbox for each of the free reports that you choose.

Comment?

Related Topix: Biotech, Healthcare Law, Law, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Arena Pharmaceuticals

Tue Apr 01, 2014

GlobeNewswire

FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind...

MannKind Corporation today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration voted 13 to 1 to recommend that AFREZZA Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be ... (more)

Comment?

Related Topix: Biotech, Food and Drug Administration, Medicine, Insulin (generic), Humulin, Novolin, Marketing, Diabetes, Health, Corporate / Securities Law, Law

BayStreet.ca

Alcoa Inc. Plans to Trim 147,000 Metric Tons of Aluminum Smelting...

AA shares closed up 3.13% on Monday with nearly 40 million shares traded. The stock was one of the most active stocks on the NYSE and hit a new yearly high of $12.97 during intra-day trading.

Comment?

Related Topix: Mining, Alcoa, Financial Markets, Day Trading, Personal Finance, Biotech, Medicine, Insulin (generic), Humulin, Novolin, Automakers, General Motors

Mon Mar 31, 2014

Benzinga

Mid-Afternoon Market Update: American Capital Rises as MannKind Shares Take a Hit

Toward the end of trading Monday, the Dow traded up 0.83 percent to 16,459.76 while the NASDAQ surged 1.12 percent to 4,202.81.

Comment?

Related Topix: Biotech, American Capital Strategies, Financial Services, Investment Services, Medicine, Insmed, Healthcare Industry, Financial Markets, Transportation, UTi Worldwide, Logistics, Momenta Pharmaceuticals

SchaeffersResearch.com

Free Falling MannKind Corporation (MNKD) Entices Options Bears

Food and Drug Administration concerns , the pharmaceutical stock is down another 16% this afternoon at $4.07, thanks to a bearish brokerage note from Piper Jaffray earlier.

Comment?

Related Topix: Biotech, Food and Drug Administration, Financial Markets, Personal Finance, Day Trading

Sun Mar 30, 2014

BayStreet.ca

Yahoo Director John Hayes to Step Down; MannKind Corp.'s Afrezza...

YHOO shares modestly closed in the green this past Friday up almost 1%. The stock traded nearly 18.3 million shares and was one of the most active stocks on the NASDAQ.

Comment?

Related Topix: Startups, Yahoo!, Biotech, Financial Markets, Marketing, Financial Services, Travelers Express Company, Retail, GameStop

Fri Mar 28, 2014

SchaeffersResearch.com

Option Clips: Ariad Pharmaceuticals, MannKind, and Kroger

StockTwits today are oncology concern Ariad Pharmaceuticals, Inc. and biopharmaceutical issue MannKind Corporation .

Comment?

Related Topix: ARIAD Pharmaceuticals, Biotech, Medicine, Healthcare Industry, Kroger, Retail, Grocery, Startups, Jazz Pharmaceuticals, Day Trading, Financial Markets, Personal Finance

The Washington Post

MannKind's Inhaled Insulin Tied to Lung Function Concerns

MannKind Corp.'s inhaled diabetes drug, found to be effective against Type 2 diabetes, is linked to potential breathing problems that may limit its use in patients with lung diseases, U.S. regulators said.

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Biotech, Diabetes, Health, Food and Drug Administration, Business News

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••
•••